Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-07-01
Rangatū:	Cardiovascular Diabetology
Ngā marau:	Diabetes mellitus Type 2 Myocardial infarction Sodium-glucose transporter 2 inhibitors
Urunga tuihono:	https://doi.org/10.1186/s12933-024-02328-6
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!